Is an injection the right next step for your joint pain?

Ongoing knee, hip or ankle pain can reach a point where an injection becomes a reasonable “next step” — typically after a period of first‑line care (such as exercise therapy, weight management, activity modification and simple pain relief) has not brought acceptable day‑to‑day function. In the 2019 American College of Rheumatology/Arthritis Foundation (ACR/AF) guideline, exercise and weight loss sit at the core of osteoarthritis care, while some injection options (particularly hyaluronic acid) are treated more cautiously because average benefits can be modest relative to cost and treatment burden. These treatments are usually delivered as ultrasound‑guided outpatient injections rather than an operation, and they are not a guaranteed fix for arthritis or cartilage loss.

Hyaluronic acid (HA) is the classic “gel injection” (viscosupplementation). It aims to improve lubrication inside an osteoarthritic joint by supplementing the joint’s synovial fluid, with the main goal being pain relief and better function rather than rebuilding cartilage or halting progression. For context, Cleveland Clinic notes viscosupplementation is FDA‑approved for knee osteoarthritis, and use in other joints (including the hip) is considered off‑label — a detail that can influence how clinicians frame the evidence and how payers view value. The 2019 ACR/AF guideline conditionally recommends against HA for knee osteoarthritis and strongly recommends against it for hip osteoarthritis, reflecting uncertainty about meaningful average benefit at a population level.

The other two injections covered here are autologous biologic options, meaning they use the patient’s own tissue. Microfragmented adipose tissue (mFAT; Lipogems‑type) is prepared from fat and then injected into the knee joint; early randomised trials (including a 78‑patient study in advanced knee osteoarthritis when used alongside arthroscopic debridement, and separate trials versus saline or versus PRP) suggest symptom improvement is possible, but protocols and follow‑up vary and long‑term durability is still being defined. Bone marrow aspirate concentrate (BMAC) is derived from bone marrow and, in the ankle, is most often discussed for focal osteochondral lesions of the talus (OLT) as a biologic “augment” to cartilage repair rather than a simple injection for generalised ankle arthritis; a 2016 systematic review found only four eligible clinical studies and described a marked lack of high‑level, long‑term evidence.

Practical decision‑making usually comes down to four factors discussed in the sections that follow:

• Likely benefit for the specific joint problem (knee osteoarthritis vs hip osteoarthritis vs talar cartilage defect).
• Risks and downtime, including short‑term flare reactions and rarer complications.
• Cost and coverage, which can differ sharply between symptom‑relief injections and autologous biologics.
• Provider expertise, including image‑guided placement (especially for the hip) and experience with biologic preparation.

Search MSK lists specialists across the UK who offer ultrasound‑guided joint injections and osteoarthritis or ankle cartilage care, with filters by region and specialty.

Are knee gel (hyaluronic acid) injections good value for money?

Value for money with hyaluronic acid (HA) “gel” injections often comes down to a simple trade-off: paying for a treatment that may reduce knee osteoarthritis pain for a limited period (often measured in months rather than years), rather than changing the underlying arthritis. Hospital for Special Surgery (HSS) notes that, when HA works, the effect commonly begins to wear off by about six months, and Cleveland Clinic describes relief that can last for months rather than being a permanent fix. The practical “value” question is therefore whether the likely improvement in day-to-day function is worth the total cost and appointment burden for that time window.

The big caution flag on cost-effectiveness comes from the 2019 American College of Rheumatology/Arthritis Foundation (ACR/AF) guideline, which conditionally recommends against HA injections for knee osteoarthritis (and strongly recommends against HA for hip osteoarthritis). In plain terms, that recommendation reflects a judgement that average benefit across large groups of patients is modest compared with the cost and hassle, especially when compared with treatments the guideline supports more strongly (such as exercise/weight loss strategies and, for the knee, intra-articular corticosteroid injections). Even with that scepticism, the guideline stance does not mean nobody benefits—rather, it frames HA as a selective option where the personal “value equation” may look better (for example, when other options are unsuitable or when delaying surgery matters).

Real-world pricing varies by country and provider, but the US data give a concrete benchmark for how costs can be structured. In one high-volume US provider’s cost guide, typical billed charges for knee HA injections were reported as about US$500–$1,200 per injection, and among 40,000+ mostly Medicare patients, about 93% reportedly paid $0 out of pocket once insurance cover was applied. That same provider frames total cost as “hundreds to a few thousand dollars” for a course, depending on how many injections are used. This kind of pattern—higher headline charges but low patient cost where insurer criteria and prior authorisation are met—helps explain why two people can have very different financial experiences of the same treatment.

Comparing injections with knee replacement also helps clarify what “value” means. Using the same US clinic’s figures, total knee replacement is described as costing on the order of US$30,000–$50,000 or more, versus a far smaller upfront cost for injections—while also acknowledging that replacement aims to be more definitive, and gel injections aim for temporary symptom relief. In UK terms, exact figures depend on clinic fees, the HA product, and whether a single injection or a series is used; funding routes may include self-pay, private medical insurance (often needing pre-authorisation), and—depending on local policy and clinical criteria—NHS commissioning, which may be influenced by guideline scepticism about average benefit.

Before agreeing to a course, the questions that most directly affect “value” are practical and specific:

• What is the total cost for the full course (including consultation, ultrasound guidance, and all injections), and is it one injection or a 3–5 week series?
• What evidence is being used to set expectations for how long benefit may last (for example, the ~6-month timeframe cited by HSS), and what happens if there is little or no improvement?
• If private insurance is involved, what are the pre-authorisation requirements, and what is the expected excess/co-pay?
• Given the 2019 ACR/AF position on HA for knee OA, what other options are being considered alongside or before HA (for example, exercise-based rehab, weight-management support, or other injections such as corticosteroid), and what is the rationale for choosing HA in this case?

What does a knee gel injection feel like and how long does it help?

Most appointments for a knee hyaluronic acid (HA) “gel” injection are set up as a short outpatient procedure, often taking place in a clinic room rather than a theatre setting. Hospital for Special Surgery (HSS) describes viscosupplementation as an in-clinic injection treatment for knee osteoarthritis, and Cleveland Clinic similarly outlines it as a straightforward joint injection given after other measures have not provided enough relief. The practical headline is that people typically go home the same day and are able to walk out after the injection, bearing weight as comfort allows.

A typical visit includes a quick check of symptoms and the knee itself, followed by skin cleaning and a small needle to numb the area with local anaesthetic. The HA is then injected into the knee joint; some services use ultrasound guidance to help with accurate placement, particularly where anatomy is difficult or when a clinician prefers image guidance. During the injection, common sensations include a brief sting from the local anaesthetic and a feeling of pressure or “fullness” in the knee as the gel goes in (the joint space is small).

Different products mean different schedules. Cleveland Clinic and HSS both describe that some HA preparations are given as a course of weekly injections over about 3–5 weeks, while other brands are designed as a single injection. Because the product determines the plan, it’s normal for two patients to have very different “course lengths” even when the diagnosis is the same knee osteoarthritis.

In the first 24–72 hours, the most common after-effects are local and short-lived: temporary soreness, warmth, stiffness or mild swelling around the knee. Cleveland Clinic notes these reactions are usually mild and settle on their own. More intense inflammatory “flare” reactions or allergic-type responses are described as uncommon (around 1% in some knee series), but they can be noticeably more painful than the typical post-injection ache.

The time course of benefit is usually gradual rather than instant. Cleveland Clinic notes that once relief starts, it can last for months, and HSS notes the effect commonly starts to wear off by about six months. In a high-volume clinic’s patient-facing summary, peak improvement is described as occurring around 4–6 weeks after treatment, with benefit then lasting several months in many people—useful context for setting expectations if the knee feels unchanged in the first week or two.

Red flags are uncommon, but the important ones are the same as for any joint injection: rapidly worsening pain and swelling over hours to a day, increasing redness or heat spreading around the knee, fever, feeling systemically unwell, or a sudden inability to weight-bear. Cleveland Clinic highlights infection (septic arthritis) and severe reactions as rare but urgent problems when they occur.

Questions to take to an appointment (so expectations match the product and plan):

• Is this HA product a single injection or a 3–5 week course (and what is the full schedule)?
• When is improvement usually noticed in this clinic—over weeks, with a possible peak around 4–6 weeks, or sooner?
• What mild reactions are most common in the first 72 hours, and what pain relief options are preferred if the knee is sore?
• What symptoms would count as an urgent same-day review (for example, fever or rapidly increasing swelling)?
• If the effect wears off by around six months (as HSS notes can happen), what is the agreed next step if symptoms return?

How do hyaluronic acid options differ for knee and hip joints?

Brand names can make hyaluronic acid (HA) injections look as if they are all fundamentally different, but in practice the biggest day‑to‑day difference is often the schedule. Cleveland Clinic and Hospital for Special Surgery (HSS) describe HA regimens that range from a single injection to a weekly course over about 3–5 weeks, which translates into very different numbers of clinic visits and (depending on the provider) different total procedural charges. This is often more relevant to decision‑making than small formulation details that are hard to compare across products.

For knee osteoarthritis, head‑to‑head evidence does not clearly favour longer courses. A level‑1 systematic review (11 comparative studies) found no consistent difference in patient‑reported outcomes between single‑injection and multi‑injection HA products, and 5‑injection series did not appear clearly superior to 3‑injection series. In other words, where HA is being considered at all, the published comparisons suggest that “more injections” does not reliably mean “better results”.

That evidence has a practical implication: if outcomes are broadly similar on average, convenience (one appointment versus three to five) and the total course cost may become the deciding factors more often than the brand. The same review explicitly flags the potential advantage of single‑injection regimens for cost‑effectiveness and patient convenience, because fewer visits typically means fewer billable procedures and less time off work.

The bigger issue, however, is whether HA is worthwhile for a particular person in the first place. The 2019 American College of Rheumatology/Arthritis Foundation (ACR/AF) guideline is conditionally against HA for knee OA and strongly against HA for hip OA, reflecting modest average benefits compared with other approaches. In that context, fine distinctions between products matter less than a clear, personalised rationale for choosing HA at all (rather than relying on marketing claims about one formulation being “stronger” or “longer lasting”).

Hip injections sit in a different category because the hip joint is deep and technically harder to access. Cleveland Clinic notes that viscosupplementation is FDA‑approved only for the knee, so HA for hip OA is generally discussed as off‑label use. Where it is offered, published series commonly use ultrasound guidance to confirm accurate joint placement; a clinical safety study (PubMed 23852899) reports a low rate of adverse events with ultrasound‑guided hip HA, and a 2024 observational cohort of 85 patients receiving ultrasound‑guided high‑density HA reported improvements in hip outcome scores and pain at 1 year, with no serious adverse events in that sample. In the same cohort, results were described as best in mild–moderate radiographic disease, while many with advanced arthritis later proceeded to hip replacement—one reason that the overall “value” case for hip HA remains uncertain despite reassuring procedural safety in experienced hands.

Useful questions to take into a consultation (knee or hip) include:

• Is the proposed product a single injection or a 3–5 week course, and what is the total number of appointments?
• For knee OA, what is the clinic’s reasoning for choosing a single versus multi‑injection regimen given the 11‑study systematic review showing no consistent outcome differences?
• What is the total cost for the full course (including ultrasound guidance if used), rather than the per‑injection price?
• If hip HA is being considered, is it being offered explicitly as off‑label, and will it be ultrasound‑guided?
• How does the clinician reconcile the plan with the 2019 ACR/AF position (conditional against knee HA; strong against hip HA), and what would count as a “stop” decision if meaningful improvement does not occur?

Who might consider microfragmented fat (mFAT) injections for knee arthritis?

Microfragmented adipose tissue (mFAT, often discussed under Lipogems-type systems) is one of the autologous “biologic” injection options that has been tested in randomised knee osteoarthritis studies, and the evidence is summarised here in plain language without interrupting the narrative with raw study links. In simple terms, a small amount of a person’s own fat is taken (often from the abdomen or upper thigh), mechanically processed into microfragmented tissue, and then placed into the knee joint—typically using image guidance such as ultrasound—to support the joint’s own repair responses rather than acting as a lubricant like hyaluronic acid.

What the outpatient pathway usually looks like

Unlike a straightforward single knee injection, mFAT is a two-part outpatient process: a short harvest step followed by the intra-articular knee injection. In published protocols, the harvest is done under local anaesthetic, using a small cannula to collect subcutaneous fat; the tissue is then processed in a closed system to create the microfragmented product before injection into the knee joint. Because there is a second treatment site (the harvest area), it is normal for consent discussions to cover expected bruising and soreness there, as well as post-injection knee flare.

What the randomised trials suggest (and what they do not)

One of the clearer signals for “added benefit” comes from a 78-patient randomised controlled trial in advanced radiographic knee osteoarthritis (Kellgren–Lawrence grade 3–4) where mFAT was used as an adjunct to arthroscopic debridement. In that study, the group receiving debridement plus mFAT reported better functional outcomes at around 6 months, and there were differences favouring the mFAT group in KOOS subscales and cartilage-related MRI T2-mapping at roughly 24 months, compared with debridement alone. This pattern is consistent with mFAT having biologic activity in the joint environment, while still falling short of proving long-term disease modification.

Separate trials have looked at mFAT as a stand-alone injection strategy. A randomised study comparing mFAT with saline control reported clinically meaningful improvements in pain and function over 12 months, suggesting the response is not simply a placebo effect in every case. Another randomised trial comparing platelet-rich plasma (PRP) with mFAT found that both groups improved and appeared safe over one year, which supports mFAT as a plausible symptom-relief option while also implying that, in at least some settings, it may not be clearly superior to other injection-based biologics.

Who tends to explore mFAT in practice

Based on who has been enrolled in randomised studies (including people with KL grade 3–4 changes) and how clinics typically position autologous biologics, mFAT is most often explored by adults with symptomatic knee osteoarthritis who are trying to improve day-to-day function and potentially delay knee replacement, particularly where standard non-operative care has not been enough. It is also a pathway that tends to come up when someone wants an autologous (own-tissue) option and accepts that the evidence base is still developing beyond the 1–2 year horizon reported in many trials.

Limits that matter before paying for a consultation

Even with randomised data, the mFAT evidence remains relatively early-stage: sample sizes are modest (for example, 78 participants in the debridement-adjunct RCT), follow-up is commonly 12–24 months, and protocols vary between studies (including whether mFAT is delivered alongside arthroscopy, the processing approach, and injection volumes). There is also little direct evidence on cost-effectiveness or on how outcomes compare with well-established pathways such as structured exercise-based rehabilitation over time, or with the more definitive symptom and function gains expected from knee replacement in appropriately selected cases.

Practical consultation questions that follow directly from the trials include: the exact plan (harvest site such as abdomen vs thigh, and whether ultrasound guidance is used), which outcome measure the clinician tracks (for example KOOS domains over 6–24 months), what would count as a “non-response”, and what the next step would be if symptoms return after 1 year.

When is bone marrow concentrate (BMAC) used for ankle cartilage problems?

Ankle bone marrow aspirate concentrate (BMAC) is most often discussed in a fairly specific scenario: a focal osteochondral lesion of the talus (OLT) — effectively a localised “pothole” involving cartilage and underlying bone in the ankle, sometimes after a significant sprain or fracture. In that setting, BMAC is usually framed as a biologic adjunct to a cartilage-repair plan for a defined talar defect, rather than as a general-purpose injection for widespread ankle osteoarthritis.

What BMAC is trying to do in the ankle (and what it isn’t)

BMAC starts with a bone marrow aspirate (commonly from the pelvis/iliac crest), which is then processed to concentrate the marrow components before being delivered to the target area. In the talus literature, BMAC is typically used to augment a repair strategy for an OLT, aiming to support the body’s own healing response at the defect site rather than acting as a lubricant (as hyaluronic acid does) or as a cartilage “replacement”. The practical implication is that the key question is often how BMAC is being used alongside other defect-focused treatments, not simply whether an ankle joint injection is being offered.

To keep the focus on decision-making rather than surgical detail, it is enough to note that published approaches often combine BMAC with a cartilage repair technique for the talar lesion, and that some pathways may include targeted placement into or around the defect rather than a stand-alone “ankle arthritis injection”. That distinction matters because a diffuse, end-stage arthritic ankle and a single OLT are different problems, with different goals and different evidence.

What the evidence base actually looks like (2016 review)

The most commonly cited overview is a 2016 systematic review of BMAC for osteochondral lesions of the talus, which found only four eligible clinical studies (largely retrospective case series, plus one prospective cohort). Across those small and heterogeneous studies, patients generally reported improvements in pain and function when BMAC was used to augment talar cartilage repair, but the review highlighted how difficult it was to draw firm conclusions because techniques varied and high-level comparative evidence was limited.

The tone of that review is notably cautious: it described an “overwhelming paucity” of robust data and recommended careful consideration until optimal techniques, ideal candidates and long-term outcomes are better defined. In practical terms, that caution tends to push decision-making towards very clear indications (a defined OLT rather than generalised arthritis) and realistic expectations about what is known — and not known — beyond the short-to-mid-term follow-up reported in early series.

Why specialist experience matters (and what to ask)

More recent work has increasingly focused on characterising what is in BMAC (its cellular composition) and relating that to outcomes in talar lesions, reinforcing that harvest technique, processing methods and application details may matter. That makes provider experience particularly important for ankle cartilage problems, where the target is small (the talar dome) and the treatment is often one part of a wider cartilage-preservation plan.

Practical questions that follow directly from the evidence and its limits include: whether the diagnosis is truly an OLT (with imaging confirmation), how BMAC will be used (as an adjunct to a defect-focused repair rather than as a catch-all arthritis treatment), what outcome measures are tracked, and what the fallback plan is if symptoms persist.

Search MSK lists specialists across the UK who manage ankle cartilage injuries and offer biologic injection options; filtering by region and ankle/foot expertise can help identify clinicians who regularly treat osteochondral lesions of the talus rather than general ankle pain alone.